Aurinia potentially has the 1st treatment for lupus nephritis, says RBC Capital’s Douglas Miehm.
Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) fell nearly 5% in after-hours trading Thursday after it notified the SEC and shareholders that it would be …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced today that its common stock has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective before market …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) served its third quarter earnings on Tuesday, but to Canaccord analyst Neil Maruoka, what matters most is the update …
H.C.
Ed Arce lifts his price target on AUPH after recent R&D day widened doors to voclosporin’s opportunity.
Neil Maruoka highlights encouraging prospects for AUPH lead asset in lupus nephritis after Analyst Day.
Elemer Piros reaffirms his bullish thesis on AUPH after a compelling R&D day mapping the next 24 months.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are rising nearly 4% in pre-market trading Friday, after the drug maker announced plans to expand its voclosoprin renal …
